|
|
Search All
|
|
|
Create a free account to unlock these features!
|
|
|
Search All
|
|
|
Create a free account to unlock these features!
| Overview | News | Financials | People | Insider Trades | Compensation | Holdings | Ownership | Corporate Family |
| Name: | Genzyme Corp |
| Revenue: | $4.52B |
| Profit: | $422.30M |
| Employees: | 12,000 |
| Headquarters: | ONE KENDALL SQ CAMBRIDGE, Massachusetts 02139 United States Of America |
| Website: | |
| Lists: |
| #196 | Worst Performers |
We are a global biotechnology company dedicated to making a major impact on the lives of people with serious diseases. Our broad product and service portfolio is focused on rare disorders, renal diseases, orthopaedics, organ transplant, diagnostic and predictive testing, and cancer. We were formed as a Delaware corporation in June 1981 and became a Massachusetts corporation in 1991. We are organized into six financial reporting units, which we also consider to be our reporting segments: ú â€Â¢
We are a global biotechnology company dedicated to making a major impact on the lives of people with serious diseases. Our broad product and service portfolio is focused on rare disorders, renal diseases, orthopaedics, organ transplant, diagnostic and predictive testing, and cancer. We were formed as a Delaware corporation in June 1981 and became a Massachusetts corporation in 1991. We are organized into six financial reporting units, which we also consider to be our reporting segments: ú â€Â¢ ú Renal, which develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure. The unit derives substantially all of its revenue from sales of Renagel (including sales of bulk sevelamer) and Hectorol; ú â€Â¢ ú Therapeutics, which develops, manufactures and distributes therapeutic products, with an expanding focus on products to treat patients
|
2 min: |
Will Sanofi and Genzyme sit down and talk?
|
|
|
|
1 hour: |
Genzyme (NASDAQ:GENZ): See 90% Probablity GENZ Gets $80/Share
...
|
|
|
|
3 hours: |
ANALYSIS-Conundrum: M&A/credit binge vs double-dip fear
|
|
|
|
8 hours: |
Future of Genzyme / Isis Pharma's Cholesterol Drug Still Up
...
|
|
|
|
19 hours: |
|
|
|
9/2/10: |
Genzyme says drug lowers cholesterol
|
|
|
|
9/1/10: |
Genzyme Options Pricing In More Upside (GENZ)
|
|
|
|
9/1/10: |
Genzyme's Termeer, Biotechnology Pioneer, May Sell
|
|
|
|
9/1/10: |
Data From Mipomersen Phase 3 Trial In heFH Patients Presented
...
|
|
|
|
9/1/10: |
Genzyme boss willing to sell but only at a higher price
|
|
| Income (in thousands of USD) |
3 months ending 2009-12-31 00:00:00 |
12 months ending 2009-12-31 00:00:00 |
| Revenue | 1,080,630 | 4,515,525 |
| Net Income | 23,245 | 422,300 |
| Balance Sheet (in thousands of USD) | ||
| Current Assets | 2,802,803 | 2,802,803 |
| Total Assets | 10,060,724 | 10,060,724 |
| Current Liabilities | 1,080,130 | 1,080,130 |
| Total Liabilities | 2,377,072 | 2,377,072 |
| Total Shareholders Equity | 7,683,652 | 7,683,652 |
| Cash Flow (in thousands of USD) | ||
| Cash from Operating Activity | 222,456 | 1,179,037 |
| Cash from Investing Activity | -184,343 | -671,424 |
| Cash from Financing Activity | 26,521 | -336,616 |
| Change in Cash | 62,687 | 170,140 |
| Key Stats |
3 months ending 2009-12-31 00:00:00 |
Trailing 12 Months |
| Gross Profit Margin | 64.80% | 69.30% |
| Net Profit Margin | 2.15% | 9.35% |
| Return on Assets | 0.23% | 4.20% |
| Return on Equity | 0.30% | 5.50% |
| Return on Invested Capital | 0.21% | 4.64% |
